Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells
Authors:
- E DonnarummaEDE Donnarumma
- M IaboniMIM Iaboni
- G RoscignoGRG Roscigno
- M GarofaloMGM Garofalo
- G RomanoGRG Romano
- D FioreDFD Fiore
- P De MarinisPMP De Marinis
- C M CroceCCC M Croce
- G CondorelliGCG Condorelli
- 10 September 2012
- journal article
- Published by Springer Nature in Oncogene
- Vol. 32 (34) , 4001-4008
Abstract
Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in treatments, survival of patients remains poor. To define novel pathways that regulate susceptibility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in glioma, we have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant glioma cells, levels of different miRs are increased, and in particular, miR-30b/c and -21. We demonstrate that these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. T98G-sensitive cells treated with miR-21 or -30b/c become resistant to TRAIL. Furthermore, we demonstrate that miR-30b/c and miR-21 target respectively the 3' untranslated region of caspase-3 and TAp63 mRNAs, and that those proteins mediate some of the effects of miR-30 and -21 on TRAIL resistance, even in human glioblastoma primary cells and in lung cancer cells. In conclusion, we show that high expression levels of miR-21 and -30b/c are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets for TRAIL resistance in glioma.Keywords
This publication has 41 references indexed in Scilit:
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaBritish Journal of Cancer, 2010
- c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activityCell Death & Differentiation, 2010
- Survival comparison between glioblastoma multiforme and other incurable cancersJournal of Clinical Neuroscience, 2010
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerBritish Journal of Cancer, 2010
- Advances in the genetics of glioblastoma: are we reaching critical mass?Nature Reviews Neurology, 2009
- PED is overexpressed and mediates TRAIL resistance in human non‐small cell lung cancerJournal of Cellular and Molecular Medicine, 2008
- TRAIL signalling: Decisions between life and deathThe International Journal of Biochemistry & Cell Biology, 2007
- TRAIL: a multifunctional cytokineFrontiers in Bioscience-Landmark, 2007
- Selective inhibition of PED protein expression sensitizes B‐cell chronic lymphocytic leukaemia cells to TRAIL‐induced apoptosisInternational Journal of Cancer, 2006
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006